Tennis Elbow

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will sponsor tennis players participating in The Championships, Wimbledon 2024 to spotlight its advanced Sports Medicine portfolio alongside some of the greatest athletes in the world. Smith+Nephew endeavours to help people live their ‘Life Unlimited’ by aiding in their recovery from injury and get them back to doing what they love. Click to play video - Smith+Nephew Proud Player Sponsor at The Championships, Wimbledon 2024 Tennis is an elegant sport but can be rough on the body – especially to a player’s joints. Two common injuries1,2 that tennis players suffer are rotator cuff tears in the shoulder and meniscus tears in the knee. Smith+Nephew offers advanced solutions for both of these injuries that are supported by clinical evidence and time-tested results. Smith+Nephew’s comprehensive Advanced Healing Solutions portfolio is redefining biological healing in rotator cuff repair. Backed by 10 years of clinical evidence and more than 100,000 procedures completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact, offering a better solution for more than 1 million3 patients having surgery for a rotator cuff tear each year. The collagen-based implant supports the body’s natural healing response to facilitate the formation of new tendon-like tissue to biologically augment the existing tendon and change the course of rotator cuff tear progression.4-10 Smith+Nephew also has an established track record of success in knee repair including a 30-year legacy of saving the meniscus rather than removing it. One of the most frequently published meniscal repair devices on the market, the FAST-FIX◊ Family of meniscal repair solutions has helped surgeons repair hundreds of thousands11 of meniscal tears over the past 30 years due to its ease of use,12 high fixation strength,*13-16 and strong, reliable repairs.17-19 With an 88% mean success rate of all-inside repairs,20 the FAST-FIX Family has truly helped patients return to a Life Unlimited. “Both Smith+Nephew and the players participating in Wimbledon share a common thread as leaders in their respective fields and being among the best at what they do,” said Christie Van Geffen, Senior Vice President of Global Marketing for Sports Medicine at Smith+Nephew. “It’s an honour to sponsor players competing in this year’s Championship and we look forward to helping athletes all over the world get back to performing at the highest level.” If you would like to find out more about Smith+Nephew’s leading Sports Medicine technology portfolio – including the REGENETEN Bioinductive Implant and FAST-FIX Family of meniscal repair solutions – please visit www.smith-nephew.com. - ends – Media Enquiries Dave Snyder +1 (978) 749-1440 Smith+Nephew david.snyder@smith-nephew.com *As demonstrated in biomechanical testing References Dines, JS et al. Tennis Injuries: Epidemiology, Pathophysiology, and Treatment. J Am Acad Orth Surg. 2015;23(3):181-189Majewski M et al.Epidemiology of athletic knee injuries: A 10-year study. The Knee. 2006;13(3):184-188iData Research. Rotator cuff repair and reconstruction market size, share and trends analysis (2023). Available at: https://idataresearch.com/product/rotator-cuff-repair-reconstruction-market-size-share-and-trends-analysis-global-2023-2029-medsuite-includes-grafts-allografts-xenograft-synthetic-and-1-more/#. Accessed December 19, 2023.Ruiz Ibán MA, Navlet MG, Marco SM, et al. Augmentation of a transosseous equivalent repair in posterosuperior non-acute rotator cuff tears with a bioinductive collagen implant decreases the re-tear rate at one year. A randomised controlled trial. Arthroscopy. Published online 12/27/2023.Bokor DJ, Sonnabend D, Deady L, et al. Evidence of healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a collagen implant: a 2-year MRI follow-up. Muscles, Ligaments Tendons J. 2016;6(1):16-25.Schlegel TF, Abrams JS, Bushnell BD, Brock JL, Ho CP. Radiologic and clinical evaluation of a bioabsorbable collagen implant to treat partial-thickness tears: a prospective multicenter study. J Shoulder Elbow Surg. 2018 27(2):242-251.Van Kampen C, Arnoczky S, Parks P, et al. Tissue-engineered augmentation of a rotator cuff tendon using a reconstituted collagen scaffold: a histological evaluation in sheep. Muscles Ligaments Tendons J. 2013;3(3):229-235.Arnoczky SP, Bishai SK, Schofield B, et al. Histologic Evaluation of Biopsy Specimens Obtained After Rotator Cuff Repair Augmented With a Highly Porous Collagen Implant. Arthroscopy. 2017;33(2):278-283Bokor DJ, Sonnabend DH, Deady L, et al. Healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a highly porous collagen implant: a 5-year clinical and MRI follow-up. Muscles, Ligaments Tendons J. 2019;9(3):338-347.McElvany MD, McGoldrick E, Gee AO, Neradilek MB, Matsen FA, 3rd. Rotator cuff repair: published evidence on factors associated with repair integrity and clinical outcome. Am J Sports Med. 2015;43(2):491-500.Internal Smith+Nephew sales data from 2023 FY STGP RMSmith+Nephew 2015.Ver/Val, Protocol/Report, FAST-FIX 360 Delivery System. Internal Report. 15000994 Rev. E.Smith+Nephew 2004. Suture performance in standard arthroscopic knots - Effects of material and design. Internal Report. 1061539 Rev. A.Smith+Nephew 2007. Internal Test Request - ULTRA FAST-FIX. Internal Report. ITR-3457.Smith+Nephew 2010.The biomechanical performance of the FAST-FIX 360 meniscal repair system. Internal Report. DOF 10600596.Smith+Nephew 2007.Evaluation of the mechanical properties of the ULTRA FAST-FIX meniscal repair system in a bovine meniscus model. Internal Report. DOF 10600342Uzun E, Misir A, Kizkapan TB, et al. Evaluation of Midterm Clinical and Radiographic Outcomes of Arthroscopically Repaired Vertical Longitudinal and Bucket-Handle Lateral Meniscal Tears. Orthop J Sports Med. 2019;7(5):1 - 8.Shearman A, Foster A, Wilson A, Risebury M, Yasen S. Excellent medium-term survival of an all-inside tensionable knotted suture device justifies repair of most meniscal tears encountered during reconstructive knee ligament surgery. Knee Surg Sports Traumatol Arthrosc. 2020:1-8.Laurendon L, Neri T, Farizon F, Philippot R. Prognostic factors for all-inside meniscal repair. A 87-case series. OTSR. 2017;103(7):1017 - 1020.Johnson, D., Souter, P., Sedgwick, M.. Clinical Performance of an All-inside Meniscal Repair Device: A Systematic Literature Review with Meta-analysis. ISAKOS. 2023. About Smith+Nephew Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.5 billion in 2023. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise. For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook. Forward-looking Statements This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations. ◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

DUBLIN--( BUSINESS WIRE )--The "United States MAXIGESIC IV Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about MAXIGESIC IV for acute pain in the United States. A detailed picture of the MAXIGESIC IV for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the MAXIGESIC IV for acute pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MAXIGESIC IV market forecast analysis for acute pain in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute pain. Drug Summary MAXIGESIC IV (paracetamol + ibuprofen), a novel, patented, dual mode-of-action non-opioid pain treatment, is a unique combination of paracetamol (known as acetaminophen in the US) 1,000 mg + ibuprofen 300 mg solution for infusion for use postoperatively in hospitals for patients for whom the use of oral analgesics is limited. This specific combination is designed to allow the maximum daily dose of paracetamol and ibuprofen and to allow for the effect of paracetamol on phenylephrine when combined, the level of phenylephrine crossing into the bloodstream effectively doubles. MAXIGESIC reduces fever and temporarily relieves pain associated with headaches, migraines, tension headaches, sinus pain, toothache, dental procedures, backache, sore throat, arthritis, tennis elbow, period pain, muscular pain, rheumatic pain, aches and pains associated with colds and flu. The drug is a unique patented combination of paracetamol and ibuprofen, proven to provide fast and effective relief from a wide range of pain symptoms. MAXIGESIC IV Analytical Perspective In-depth MAXIGESIC IV Market Assessment This report provides a detailed market assessment of MAXIGESIC IV for acute pain in the United States. This segment of the report provides forecasted sales data from 2023 to 2032. MAXIGESIC IV Clinical Assessment The report provides the clinical trials information of MAXIGESIC IV for acute pain covering trial interventions, trial conditions, trial status, start and completion dates. Report Highlights In the coming years, the market scenario for acute pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MAXIGESIC IV dominance. Other emerging products for acute pain are expected to give tough market competition to MAXIGESIC IV and launch of late-stage emerging therapies in the near future will significantly impact the market. A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MAXIGESIC IV in acute pain. Our in-depth analysis of the forecasted sales data of MAXIGESIC IV from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MAXIGESIC IV in acute pain. Key Questions Answered What is the product type, route of administration and mechanism of action of MAXIGESIC IV? What is the clinical trial status of the study related to MAXIGESIC IV in acute pain and study completion date? What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MAXIGESIC IV development? What are the key designations that have been granted to MAXIGESIC IV for acute pain? What is the forecasted market scenario of MAXIGESIC IV for acute pain? What are the forecasted sales of MAXIGESIC IV in the United States? What are the other emerging products available and how are these giving competition to MAXIGESIC IV for acute pain? Which are the late-stage emerging therapies under development for the treatment of acute pain? Key Topics Covered: 1. Report Introduction 2. MAXIGESIC IV Overview in Acute pain 2.1. Product Detail 2.2. Clinical Development 2.2.1. Clinical studies 2.2.2. Clinical trials information 2.2.3. Safety and efficacy 2.3. Regulatory Milestone 2.4. Other Developmental Activities 2.5. Product Profile 3. Competitive Landscape (Marketed Therapies) 4. Competitive Landscape (Late-stage Emerging Therapies) 5. MAXIGESIC IV Market Assessment 5.1. Market Outlook of MAXIGESIC IV in Acute pain 5.2. The United States Analysis 5.2.1. Market Size of MAXIGESIC IV in the United States for Acute pain 6. SWOT Analysis 7. Analysts' Views For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/yk65yr About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

AAOS encourages patients to do their research, understand their options and find a reputable physician ROSEMONT, Ill., Aug. 15, 2023 /PRNewswire/ -- As orthopaedic medicine continues to advance through innovation, research and evidence-based medicine, the complexities and unknowns about newer treatments such as orthobiologics, may leave patients wondering if it is a viable treatment option for them. Orthobiologics, sometimes referred to as regenerative medicine, have shown great promise to treat conditions such as osteoarthritis; however, patients are seeking resources to understand if the treatment is right for them. To educate patients, the American Academy of Orthopaedic Surgeons (AAOS) developed an FAQ published on OrthoInfo.org, that outlines what orthobiologics are and the potential risks and benefits. Orthobiologics are a class of therapies that use biological products from human, animal or micro-organism sources such as cells, tissues or blood products like platelet-rich plasma (PRP), to leverage the body's natural physiology, and help enhance the body's healing process.i According to the FAQ, orthobiologics can be used by orthopaedic specialists to: Help relieve pain and inflammation from certain orthopaedic conditions, such as early osteoarthritis, which may help delay or negate the need for surgery Enhance the body's ability to heal from a repetitive use injury, such as a tendon strain or chronic anatomic change to the tendon known as tendinopathy In some cases, improve healing after orthopaedic surgery AAOS recognizes the potential orthobiologics could have on the future of musculoskeletal patient care, but recommends the need for additional evidence-based research and education for physicians and clear information for patients. "Many of my patients want to know more about orthobiologics and if it's worth the hype," said Jason L. Dragoo, MD, FAAOS, chair of the AAOS Devices, Biologics and Technology Committee and professor and vice chair of Academic Affairs for Colorado University Department of Orthopaedics in Denver. "While we are witnessing huge advancements in orthobiologics that have shown promise for patients suffering from knee osteoarthritis and tendinopathies, such as tennis elbow, I would encourage everyone to do their homework because it is not a viable treatment option for everyone. The regenerative therapies touted in radio ads or featured on highway billboards may not be grounded in science." Dr. Dragoo recommends patients work with a reputable physician, ideally one who does clinical research in this area and tracks their patient-outcome results. While trustworthy doctors can be found in many areas, if an orthopaedic surgeon is board certified and a fellow of the American Academy of Orthopedic Surgeons (FAAOS), it means they have met the rigorous professional and ethical standards established by AAOS. Dr. Dragoo also advises patients to: Avoid physicians who tout "stem cell therapy" or claim they can cure various musculoskeletal conditions in addition to pancreas, liver and kidney disorders, baldness and eyesight issues, as these violate the U.S. Food and Drug Administration (FDA) regulations on the use of biologics Speak to a physician about treatment options and then take the time to research those options, as well Ensure a physician conducts a full medical exam and inquiries about any systemic illnesses such as rheumatoid arthritis, lupus or cancer Determine if your insurance company will cover orthobiologic treatment, and if not, understand the out-of-pocket costs associated with the procedure "There are still a lot of unanswered questions and until we have those answers, we should proceed with caution," said Dr. Dragoo. "The AAOS is leading discussions with the FDA and other leading orthopaedic industry representatives to create evidence-based, unbiased information and guide advancements in the next five years that will help ensure more beneficial and targeted orthobiologic treatments for specific conditions." For more information about orthobiologics, visit OrthoInfo.org. About the AAOS With more than 39,000 members, the American Academy of Orthopaedic Surgeons is the world's largest medical association of musculoskeletal specialists. The AAOS is the trusted leader in advancing musculoskeletal health. It provides the highest quality, most comprehensive education to help orthopaedic surgeons and allied health professionals at every career level to best treat patients in their daily practices. The AAOS is the source for information on bone and joint conditions, treatments and related musculoskeletal healthcare issues; and it leads the healthcare discussion on advancing quality. Follow the AAOS on Facebook, Twitter, LinkedIn and Instagram. i AAOS Hosts Symposium on Orthobiologics. American Academy of Orthopaedic Surgeons. Accessed June 27, 2023. . SOURCE American Academy of Orthopaedic Surgeons